Skip to content
★ Sign in to follow
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. logo

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. Stock: price and insider trades · China

药易购

CN·Mcap CN¥2.1BHealth Care

No insider purchase over the last 90 days. The latest, by 艾英萍, was filed 18 Jul 2022.

Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.: what insiders have been doing

This page follows insider dealings at Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. The past year has been quiet: not a single insider filing for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. The previous disclosure was published on 3 July 2025.

Since 2022, the database holds 1 purchase and 8 sales by insiders of the company.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Insider Decl.
9
Thresholds
n/a
Buy Volume
€5,005
1 ops. · all time
Sell Volume
€6M
8 ops. · all time

Who traded when

BuySale
田文书1 sale

Since the insiders bought

  • Filed 18 Jul 2022 · 1574 days ago · €5,005
    +7.5%
    Entry CN¥31.36 · Close at T+365 CN¥33.72

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 24,682 of 26,911 companies
19.7
score / 100
Value
21
Quality
18
FCF yld-1.0%
Earn yld-0.6%
EV/EBITDA53.5x
ROE-2.1%
Gross mgn10%
Net mgn-0.3%
Debt/EBITDA7.3x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥22.32
Analyst consensus
·
Income statement
RevenueCN¥4.5B
Gross profitCN¥463.9M10% margin
EBITDACN¥46.2M1% margin
Net income-CN¥12.9M-0.3% margin
Valuation
P/Book2.6x
Beta0.05
Balance sheet & cash
Market capCN¥2.1B
Total debtCN¥337.8M
Free Cash Flow-CN¥20.8M
Debt / Equity37%
Profitability & ownership
ROE-2.1%
ROA0.3%
% insiders54.4%
% institutions0.6%
Last declaration on 3 July 2025
Declarations9 total
  • ▼
    监事Executives
    14M CNY10SZSE
    480,000 shares29.3% of flowA股XSHESZSE:173000009162987040
  • ▼
    监事Executives
    20M CNY12SZSE
    595,500 shares45.3% of flowA股XSHESZSE:173000006753779680
  • ▼
    监事Executives
    11M CNY10SZSE
    337,000 shares25.5% of flowA股XSHESZSE:173000006745305300
  • ▼
    董事Executives
    19,176 CNY15SZSE
    600 shares100.0% of flowA股XSHESZSE:173000006041552640
  • ▼
    董事Executives
    37,716 CNY12SZSE
    1,200 shares52.2% of flowA股XSHESZSE:173000005700821900
  • ▲
    董事Executives
    34,298 CNY12SZSE
    1,100 shares47.8% of flowA股XSHESZSE:173000005696586180
    Canonical exit: 16 Oct 2022 (T+90)
  • ▼
    董秘,董事,高管Executives
    2M CNY27SZSE
    66,500 shares88.7% of flowA股XSHESZSE:173000005599132670
  • ▼
    高管Executives
    2M CNY31SZSE
    62,000 shares100.0% of flowA股XSHESZSE:173000005599132580
  • ▼
    董秘,董事,高管Executives
    255,510 CNY8SZSE
    8,500 shares11.3% of flowA股XSHESZSE:173000005599132640

9 of 9 declarations

About Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.

药易购 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHE market. It specializes in the online sale of pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations